Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $138.0052W HIGH $230.49
Volume
450.34 K
Value Traded
146.53 M
Short % Float
3.97%
+2.91%Week
+7.37%1 Month
+13.62%3 Month
+30.81%6 Month
-32.16%5 Year
+6,722.46%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
33.39 B
EPS (TTM)
5.65
P/E Ratio
40.06
Ent. Value
39.40 B
Total Shares
147.80 M
Float Shares
146.64 M
Insiders
0.75%
Institutions
98.64%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
BIIB Catalyst Timeline
Dated clinical, regulatory and corporate events for Biogen Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Biogen Inc.
655Total events
27Upcoming
292Tier-1 (high impact)
2009 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Long Term DataLitifilimabClinical Data
Longest dataset reported for litifilimab in CLE with consistent safety profile
cutaneous lupus erythematosussource ↗
▲Oral PresentationLitifilimabPresentation
Litifilimab 52-week AMETHYST data presented at EADV 2026
cutaneous lupus erythematosus (CLE)source ↗
▲Topline ReadoutLitifilimabClinical Data
52-week results from Phase 2 part of AMETHYST presented at EADV 2026
cutaneous lupus erythematosussource ↗
▲PublicationEMPAVELIApprovedPresentation
Phase 3 VALIANT adolescent subgroup analysis published in Clinical Journal of the American Society of Nephrology
C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN)source ↗
▲FDA ApprovalFDA Decision
LEQEMBI Pen (SC lecanemab) approved in Japan for early Alzheimer's disease
Early Alzheimer's Diseasesource ↗
▲NMPA NDA ApprovalLecanemabApprovedEx-US Regulatory
NMPA approved subcutaneous formulation of LEQEMBI for early AD
early Alzheimer's diseasesource ↗
▲Oral PresentationzorevunersenPresentation
Presentation of 4-year OLE data at 16th European Epilepsy Congress
Dravet syndromesource ↗
▲FDA ApprovalLecanemabApprovedFDA Decision
Approval obtained in China for subcutaneous initiation treatment (500 mg)
Alzheimer's Diseasesource ↗
▲NMPA NDA ApprovalLecanemabApprovedEx-US Regulatory
LEQEMBI subcutaneous initiation treatment (500 mg) approved in China
Alzheimer's Disease (subcutaneous initiation treatment, 500 mg)source ↗
▲Other Regulator MilestoneLecanemabApprovedEx-US Regulatory
CDA-AMC issues final positive recommendation for LEQEMBI reimbursement
early Alzheimer's diseasesource ↗
▲Product LaunchPost-Market
LEQEMBI IQLIK autoinjector now available in the U.S. for initiation therapy
early Alzheimer's diseasesource ↗
◆Oral PresentationDiranersenPresentation
Phase 2 CELIA data presented at AAIC 2026
early Alzheimer's diseasesource ↗
◆Topline ReadoutDiranersenClinical Data
Topline results from CELIA previously reported
early Alzheimer's diseasesource ↗
▼Primary Endpoint MissedDiranersenClinical Data
CELIA did not meet primary endpoint of dose response on CDR-SB
early Alzheimer's diseasesource ↗
▲Oral PresentationLecanemabApprovedPresentation
LEADER Study results presented at AAIC 2026
early Alzheimer's diseasesource ↗
◆Full ResultsDiranersenClinical Data
Full results from Phase 2 CELIA study presented at AAIC
early Alzheimer's diseasesource ↗
▲Full ResultsLecanemabApprovedClinical Data
Interim analysis of LEADER study with 432 patients
early Alzheimer's diseasesource ↗
▲FDA ApprovalFDA Decision
FDA approval of LEQEMBI IQLIK subcutaneous autoinjector for initiation treatment
Alzheimer's diseasesource ↗
◆Oral PresentationLecanemabApprovedPresentation
LEQEMBI subcutaneous autoinjector data presented at AAIC 2026
early Alzheimer's diseasesource ↗
▲FDA ApprovalLecanemabApprovedFDA Decision
LEQEMBI subcutaneous initiation treatment (500 mg) approved in the U.S.
Alzheimer's Disease (subcutaneous initiation treatment, 500 mg)source ↗
◆Poster PresentationFelzartamabFiledPresentation
TRANSCEND and TRANSPIRE: phase 3 and 2 trials of the anti-CD38 antibody felzartamab in kidney transplant recipients with antibody medical rejection or isolated microvascular inflammation
Antibody mediated rejection or isolated microvascular inflammationsource ↗
◆Oral PresentationpegcetacoplanPresentation
Pegcetacoplan for Posttransplant Patients with Complement 3 Glomerulopathy or Primary (Idiopathic) Immune-Complex membranoproliferative Glomerulonephritis
Posttransplant C3G or primary IC-MPGNsource ↗
◆Poster PresentationPresentation
Establishing a central pathology review process and adjudication framework to standardize biopsy-based endpoints in transplant clinical trials
Transplant clinical trialssource ↗
◆Oral PresentationFelzartamabFiledPresentation
Prolonged CD38 Targeting with Felzartamab Achieves Sustained Suppression of Antibody-mediated Rejection: Biomarker-guided Open-label Phase 2 Extension
Antibody-mediated rejection (AMR)source ↗
◆Poster PresentationpegcetacoplanPresentation
Pegcetacoplan population pharmacokinetics and exposure-response analysis in adolescent and adult patients with C3G or primary IC-MPGN
C3G or primary IC-MPGNsource ↗
▲Breakthrough Therapy DesignationSalanersenDesignation
FDA granted Breakthrough Therapy Designation for salanersen in SMA
spinal muscular atrophysource ↗
▲Poster Presentationdapirolizumab pegolPresentation
Poster presentation at EULAR 2026 showing steroid tapering and disease control data
systemic lupus erythematosussource ↗
▲Abstractdapirolizumab pegolPresentation
Abstract AB1163 on flare rates using alternative definitions
systemic lupus erythematosussource ↗
◆Oral PresentationpegcetacoplanPresentation
Pegcetacoplan treatment response in VALIANT/VALE: Impact of disease chronicity in C3G and primary IC-MPGN
C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN)source ↗
◆Trial InitiationSalanersenTrial
Recruitment expected to begin for STELLAR-2 Phase 3 study
spinal muscular atrophysource ↗
▲Full Resultsdapirolizumab pegolClinical Data
Publication of Phase 3 PHOENYCS GO full results in The Lancet
systemic lupus erythematosussource ↗
▲Primary Endpoint Metdapirolizumab pegolClinical Data
Primary endpoint met: BICLA response at Week 48
systemic lupus erythematosussource ↗
▲Trial Initiationdapirolizumab pegolTrial
Confirmatory Phase 3 PHOENYCS FLY trial recruiting
systemic lupus erythematosussource ↗
◆FDA ApprovalLecanemabApprovedFDA Decision
Potential FDA approval of LEQEMBI IQLIK subcutaneous starting dose
Alzheimer's disease (early AD)source ↗
◆PDUFA DateLecanemabApprovedRegulatory Filing
PDUFA action date of May 24, 2026 for subcutaneous initiation treatment sBLA in US
Early Alzheimer's Diseasesource ↗
▼Primary Endpoint MissedBIIB122DiscontinuedClinical Data
Phase 2b LUMA study did not meet primary endpoint of Time to Confirmed Worsening in MDS-UPDRS Part II and III combined score
early-stage Parkinson's diseasesource ↗
▼Program DiscontinuationBIIB122DiscontinuedCorporate
Discontinuation of development of BIIB122 in idiopathic Parkinson's disease
idiopathic Parkinson's diseasesource ↗
▲Partnership / LicenseCorporate
Biogen announces research collaboration with Dayra Therapeutics to discover oral macrocyclic peptides for immunological conditions
●Major Amendment SubmittedLecanemabApprovedRegulatory Filing
FDA determines additional information constitutes major amendment to sBLA for lecanemab subcutaneous starting dose
early Alzheimer's diseasesource ↗
◆Topline ReadoutDiranersenClinical Data
Topline results from Phase 2 CELIA study of diranersen announced
early Alzheimer's diseasesource ↗
▲Interim AnalysisLecanemabApprovedTrial
Interim analysis of LEADER study with 432 patients as of May 2026
early Alzheimer's diseasesource ↗
▲FDA ApprovalNusinersenApprovedFDA Decision
SPINRAZA High Dose Regimen approved in the U.S.
spinal muscular atrophysource ↗
▲Primary Endpoint MetLitifilimabClinical Data
Second positive Phase 2 CLE dataset for litifilimab showing meaningful reduction of disease activity at Week 16
cutaneous lupus erythematosussource ↗
▲Additional DataSalanersenClinical Data
Additional Phase 1b data for salanersen showed new motor milestones in children with SMA after prior gene therapy
spinal muscular atrophysource ↗
▲Long Term DataLecanemabApprovedClinical Data
LEQEMBI real-world persistence data: ~78% of patients continued at 18 months
Alzheimer's diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How BIIB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-08-20 | Empaveli (pegcetacoplan) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
B75 / 100
Pipeline Score
$9.8B
Pipeline Value
$39.6B
Commercial Value
Undervalued
Valuation Signal
37
Drugs Scored
1.0x
rNPV / MCap
Top 4%
Mid Cap(rank 27 of 658)
Percentile Rank
Biogen Inc. holds a solid B-grade pipeline (75/100), with $11.6B risk-adjusted pipeline value, led by Litifilimab in Subacute Cutaneous Lupus Erythematosus (Phase 3).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $10.0B x 4.0 = $39.6B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| anti-CD20 therapeutic programs | $1.9B | $1.8B | +10.9% |
| TYSABRI | $1.7B | $1.7B | +3.9% |
| SPINRAZA | $1.5B | $1.6B | -7% |
| VUMERITY | $771M | $686M | +12.5% |
| AVONEX | $684M | $691M | -0.9% |
| SKYCLARYS | $585M | $459M | +27.5% |
| TECFIDERA | $480M | $860M | -44.2% |
| BENEPALI | $459M | $467M | -1.7% |
| PLEGRIDY | $241M | $256M | -5.8% |
| IMRALDI | $184M | $199M | -7.9% |
| QALSODY | $116M | $58M | +98.6% |
| SYFOVRE | $97M | - | - |
Top 12 of 15 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Litifilimab Monoclonal antibodyNCT04961567 | Systemic Lupus Erythematosus | Phase 3 | ACTIVE NOT_RECRUITING | 2,347 | Mar 16, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every BIIB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| litifilimab Breakthrough | cutaneous lupus erythematosus | Phase 2 | 2026-10-02 | clear or almost clear skin: 27.2%; CLASI 70 improvement: 28.8%; clear or almost clear skin week 24: 19.0%; CLASI 70 week 24: 21.7%Read More | Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus ErythematosusRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Godbout SeanOfficer (Chief Accounting Officer) | Option | 27 1,466.985 held | $0.00 | 10/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BIIB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0.9 % (125 %) | 59.67 M | 276.17 K | 122.72% ( 152.17 K) |
BIIB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-23 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BIIB ranks across every disease it competes in
Competitive Position is a premium feature
See how BIIB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBIIB News
BIIBBiogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
Biogen announced positive 52-week results from the Phase 2 part of the AMETHYST study for litifilimab, a potential first-in-class therapy for cutaneous lupus erythematosus (CLE). Participants showed continued improvement in skin disease activity, with over a quarter achieving clear or almost clear skin. The treatment demonstrated a rapid onset of effects, and its safety profile remained consistent with previous studies.
Read more →BIIBPhase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
Biogen announced the publication of Phase 3 VALIANT study results for EMPAVELI, showing significant benefits in adolescents with C3G and primary IC-MPGN. The study revealed a 75% reduction in proteinuria and stabilization of kidney function. This treatment is now the only approved option for this age group, following a recent FDA label update. The findings underscore the potential of EMPAVELI to improve kidney health in young patients.
Read more →BIIBBiogen to Report Third Quarter 2026 Financial Results October 28, 2026
Biogen Inc. will announce its third quarter 2026 financial results on October 28, 2026, before market opening. Following the announcement, a live webcast will be held with company management at 8:30 a.m. ET. The webcast will be accessible via Biogen's investor website and archived for 90 days.
Read more →BIIBLEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
Eisai Co., Ltd. and Biogen Inc. announced the approval of LEQEMBI Pen in Japan, a subcutaneous formulation for treating early Alzheimer's disease. This new administration method allows patients to self-administer the treatment at home, enhancing convenience and potentially reducing the burden of clinic visits. The approval follows positive results from clinical studies demonstrating comparable efficacy to intravenous administration.
Read more →BIIBStoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Stoke Therapeutics and Biogen presented long-term clinical data on zorevunersen at the 16th European Epilepsy Congress. The Phase 1/2a open-label extension studies demonstrated significant and sustained reductions in seizures, alongside improvements in cognitive and behavioral outcomes for patients receiving the investigational treatment in conjunction with standard anti-seizure medications.
Read more →BIIBLEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
Eisai and Biogen announced that China's NMPA approved LEQEMBI's subcutaneous formulation for early Alzheimer's disease treatment. This marks the first anti-amyloid therapy allowing at-home administration, enhancing patient convenience. The regimen involves a weekly self-administered injection, which may reduce healthcare resource demands and improve treatment adherence. The approval follows positive results from the Phase 3 Clarity AD study.
Read more →BIIBStoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Stoke Therapeutics and Biogen presented data from Phase 1/2a studies on zorevunersen at the 16th European Epilepsy Congress. The findings indicate potential disease-modifying effects, with sustained improvements in cognition and behavior over four years. Additionally, the treatment showed durable seizure reductions and a well-tolerated safety profile.
Read more →BIIBFinal CDA-AMC Recommendation Brings Canadians with Early-Stage Alzheimer's Disease One Step Closer to Accessing LEQEMBI® (lecanemab)
The Canadian Drug Agency's Advisory Committee (CDA-AMC) has recommended the approval of LEQEMBI (lecanemab) for Canadians with early-stage Alzheimer's disease. This recommendation is a significant step towards improving access to this promising treatment, which has shown efficacy in clinical trials. The decision underscores the importance of advancing care options for Alzheimer’s patients in Canada.
Read more →BIIBCanada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease
Eisai Co., Ltd. and Biogen Inc. announced that Canada's Drug Agency has issued a final positive recommendation for public reimbursement of LEQEMBI (lecanemab) for early Alzheimer's disease. This decision is expected to improve access to the treatment for eligible patients in Canada, marking a significant advancement in Alzheimer's care.
Read more →BIIBBiogen to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Biogen Inc. announced that its CEO, Christopher A. Viehbacher, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The event is scheduled for September 14, 2026, at 9:15 AM. This participation underscores Biogen's commitment to engaging with the healthcare sector.
Read more →BIIBBiogen entscheidet sich für Veeva Vault CRM
Biogen has chosen Veeva Vault CRM as its global sales platform to improve the delivery of medications to patients. This partnership aims to implement adaptable marketing strategies for complex therapies, enhancing customer satisfaction and innovation. Veeva's technology will support a new AI-driven business model, ensuring more patients receive the appropriate medications.
Read more →BIIBBiogen to Participate in the Wells Fargo 21st Annual Healthcare Conference
Biogen Inc. will participate in the Wells Fargo 21st Annual Healthcare Conference, featuring a fireside chat with CFO Robin Kramer and Head of Corporate Development Adam Keeney. The event aims to enhance investor relations and provide insights into the company's strategies. The webcast is scheduled for September 9.
Read more →BIIBVeeva Vault CRM seleccionado por Biogen
Biogen has selected Veeva Vault CRM as its global commercial platform to enhance its drug delivery capabilities. This strategic partnership aims to improve patient access to transformative medications. Veeva's advanced technology will support Biogen's efforts in navigating complex treatment landscapes. Both companies emphasize their commitment to customer experience and innovation.
Read more →BIIBBiogen a choisi Veeva Vault CRM
Biogen has selected Veeva Vault CRM as its global commercial platform to accelerate drug delivery to patients. This partnership emphasizes a shared commitment to customer experience and innovation. Veeva's technology aims to enhance access to medications tailored to patient needs, supporting a new commercial model based on artificial intelligence.
Read more →BIIBVeeva Vault CRM Selected by Biogen
Biogen has selected Veeva Vault CRM as its global commercial platform to enhance the delivery of medicines. This partnership aims to leverage advanced capabilities and AI to improve patient outcomes. Both companies emphasize their commitment to customer experience and innovation, marking a significant step in their collaboration.
Read more →BIIBLEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease
Eisai Co., Ltd. and Biogen Inc. have announced the availability of LEQEMBI IQLIK, the first anti-amyloid treatment allowing for at-home dosing for early Alzheimer's disease. This innovative therapy is approved in the U.S. and provides a weekly dosing option for patients, enhancing accessibility and convenience for treatment initiation and maintenance.
Read more →BIIBLEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
Eisai and Biogen have launched LEQEMBI IQLIK, a subcutaneous autoinjector for treating early Alzheimer's disease in the U.S. This innovative treatment allows for at-home administration, enhancing convenience and flexibility for patients. The regimen includes a weekly dosage of 500 mg for initiation, transitioning to 360 mg for maintenance after 18 months. While the treatment offers significant benefits, it carries risks such as amyloid-related imaging abnormalities (ARIA) that require careful monitoring.
Read more →BIIBBiogen Completes Acquisition of RayThera Inc.
Biogen has completed the acquisition of RayThera Inc., enhancing its immunology portfolio with new assets aimed at treating immune-mediated conditions. The lead program from this acquisition has already entered Phase 1 development. This move reflects Biogen's commitment to diversifying its pipeline and investing in immunology as a key growth area.
Read more →BIIBBiogen Reports Second Quarter 2026 Results
Biogen has released its financial results for the second quarter of 2026. The report includes details relevant to stockholders and stakeholders. Further communications and presentations are available for those interested in the company's performance.
Read more →BIIBBiogen Appoints Michael J. Parini as Chief Legal Officer
Biogen has appointed Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini, who has over 20 years of experience in the biopharmaceutical industry, will oversee Biogen's global legal and compliance functions. His previous roles include CEO of Spur Therapeutics and leadership positions at Vertex Pharmaceuticals and Pfizer.
Read more →About Biogen Inc.
Headquarters225 BINNEY STREET, CAMBRIDGE, MA, 02142
BIOPHARMAWATCH ELITE PLUS
Trade the next BIIB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime